Daily Brief Japan: Hogy Medical, Strike, Hokkoku Financial Holdings, Mitsubishi Kakoki Kaisha, Itochu Enex, Jcr Pharmaceuticals, Kanematsu Corp, Logizard, Meiwa Corp, Olba Healthcare Holdings and more

• Hogy Medical (3593 JP) , in the last 10 fiscals, witnessed sales grow at CAGR of 1%. In tandem with that, company reported 4% drop sales to ¥18.9B in H1FY26.
• The company revised FY26 sales guidance downwards to ¥39.2B (from previous ¥41.8B), with profits also witnessing considerable downward revision.
• Stock to underperform and so we recommend a SELL on Hogy at this moment. Strategically, two possible outcomes open for Hogy, a take-over by another corporate entity or going private.

• FY09/25 revenue was JPY20.3bn (+12.0% YoY), with operating profit at JPY6.3bn (-6.5% YoY) and net income JPY4.7bn (-4.7% YoY).
• Strike forecasts FY09/26 revenue of JPY24.3bn (+19.8% YoY) and operating profit of JPY8.4bn (+32.2% YoY).
• The company plans an annual dividend of JPY180.0 per share, maintaining a payout ratio of 60.2%.

• Consolidated ordinary income increased by 19.6% YoY to JPY53.7bn, driven by higher interest and dividend income.
• Hokkoku Bank’s core gross profit grew 23.9% YoY to JPY24.5bn, with a 50.0% rise in core operating profit.
• Non-performing loans at Hokkoku Bank totaled JPY78.3bn, with a 0.25pp YoY decline in percentage of total credit.

• The company reported a 35.7% YoY revenue increase to JPY36.1bn and a 65.4% YoY rise in operating profit.
• Revised full-year FY03/26 forecast: revenue JPY88.5bn, operating profit JPY8.6bn, recurring profit JPY8.7bn, net income JPY5.9bn.
• Engineering segment revenue rose 25.8% YoY, with a 1,201.4% surge in operating profit, OPM at 4.6%.

• In Q2 FY03/26, Itochu Enex reported sales revenue of JPY411.7bn, operating profit of JPY11.2bn, and net profit of JPY6.9bn.
• Car-Life Division’s sales revenue was JPY289.26bn, with operating profit down 39.8% YoY, and net profit down 29.8% YoY.
• Industrial Business Division’s sales revenue was JPY55.3bn, operating profit up 7.5% YoY, and net profit up 10.9% YoY.

• Jcr Pharmaceuticals (4552 JP) has reported in-line performance for H1FY26. While mainstay product is facing pricing and competitive pressure, one-off licensing income has driven overall performance.   
• JCR is expected to meet FY26 guidance. H1FY26 sales, operating profit, and net profit represent progress rate of 56.5%, 91.5%, and 57.0%, against full-year guidance, respectively.
• Heavy dependence on one major product, which is subject to pricing and competitive pressure, and no major product launch lined up anytime soon are key near-term risks.

• Companywide revenue decreased by 1.0% YoY, while profit attributable to owners increased by 6.6% YoY.
• Strong performance in mobile and ICT segments boosted profits, despite declines in iron, steel, and energy.
• Equity ratio attributable to owners was 28.3%, with net interest-bearing debt-to-equity ratio at 0.59x.

Key points (machine generated)

• Logizard Co., Ltd. reported a 10.1% increase in net sales to ¥2,177 million and a 17.8% rise in operating profit to ¥408 million for FY6/25, driven by cloud services.
• The company focuses on inventory management systems for retail and logistics, offering subscription-based solutions like Logizard ZERO and Logizard OCE.
• For FY6/26, Logizard expects a 12.1% increase in net sales but a decline in operating profit due to investments, aiming for significant growth by FY6/28.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• Revenue decreased 1.8% YoY; operating profit rose 44.6% YoY; recurring profit increased 20.5% YoY; net income grew 14.5% YoY.
• Meiwa’s FY03/26 forecast: revenue JPY160.0bn (+2.1% YoY), operating profit JPY3.2bn (-10.3% YoY), recurring profit JPY4.0bn (-11.5% YoY).
• Meiwa plans a JPY38.00 per share dividend for FY03/26, reflecting lower net income expectations.

• The company’s Q1 FY06/26 sales were JPY30.8bn (+6.1% YoY), with operating profit at JPY259mn (-7.3% YoY).
• Medical Devices and Consumables segment sales rose 5.2% YoY, driven by consumables and equipment sales growth.
• SPD segment sales increased 6.3% YoY, but operating profit declined 31.4% YoY due to rising SG&A expenses.